Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Japanese Journal of Ophthalmology
Published in: Japanese Journal of Ophthalmology 4/2013

01-07-2013 | Laboratory Investigation

Effects of l-arginine on anatomical and electrophysiological deterioration of the eye in a rodent model of nonarteritic ischemic optic neuropathy

Authors: Hideki Chuman, Tomoyuki Maekubo, Takako Osako, Michitaka Ishiai, Naoko Kawano, Nobuhisa Nao-i

Published in: Japanese Journal of Ophthalmology | Issue 4/2013

Login to get access

Abstract

Purpose

The aims of this study were to clarify the effectiveness of l-arginine (1) for reducing the severity of anatomical changes in the eye and improving visual function in the acute stage of a rodent model of nonarteritic ischemic optic neuropathy (rNAION) and (2) in preventing those changes in anatomy and visual function.

Methods

For the first aim, l-arginine was intravenously injected into rats 3 h after rNAION induction; for the second aim, rNAION was induced after the oral administration of l-arginine for 7 days. The inner retinal thickness was determined over time by optical coherence tomography, and the amplitude of the scotopic threshold response (STR) and the number of surviving retinal ganglion cells (RGCs) were measured. These data were compared with the baseline data from the control group.

Results

Both intravenous infusion of l-arginine after rNAION induction and oral pretreatment with l-arginine significantly decreased optic disc edema in the acute stage and thinning of the inner retina, reduced the decrease in STR amplitude, and reduced the decrease in the number of RGCs during rNAION.

Conclusion

Based on these results, we conclude that l-arginine treatment is effective for reducing anatomical changes in the eye and improving visual function in the acute stage of rNAION and that pretreatment with l-arginine is an effective therapy to reduce the severity of the condition during recurrence in the other eye.
Literature
1.
Arnold AC. Ischemic optic neuropathy. In: Miller NR, Newman NJ, editors. Walsh & Hoyt’s Clinical Neuro-Ophthalmology. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2005. p. 349–84.
2.
Hattenhauer MG, Leavitt JA, Hodge DO, Grill R, Gray DT. Incidence of nonarteritic ischemic optic neuropathy. Am J Ophthalmol. 1997;123:103–7.PubMed
3.
The Ischemic Optic Neuropathy Decompression Trial Research Group. Optic nerve decompression surgery for nonarteritic anterior ischemic optic neuropathy (NAION) is not effective and may be harmful. JAMA. 1995;273:625–32.CrossRef
4.
Beri M, Klugman MR, Kohler JA, Hayreh SS. Anterior ischemic optic neuropathy. VII. Incidence of bilaterality and various influencing factors. Ophthalmology. 1987;84:1020–8.
5.
Atkins EJ, Bruce BB, Newman NJ, Biousse V. Treatment of nonarteritic anterior ischemic optic neuropathy. Surv Ophthalmol. 2010;55:47–63.PubMedCrossRef
6.
Hayreh SS, Zimmerman MB. Nonarteritic anterior ischemic optic neuropathy: role of systemic corticosteroid therapy. Graefes Arch Clin Exp Ophthalmol. 2008;246:1029–46.PubMedCrossRef
7.
Arnold AC, Hepler RS, Lieber M, Alexander JM. Hyperbaric oxygen therapy for nonarteritic ischemic optic neuropathy. Am J Ophthalmol. 1996;122:535–41.PubMed
8.
Fujikado T, Morimoto T, Matsushita K, Shimojo H, Okawa Y, Tano Y. Effect of transcorneal electric stimulation in patients with non-arteritic ischemic optic neuropathy or traumatic optic neuropathy. Jpn J Ophthalmol. 2006;50:266–73.PubMedCrossRef
9.
Bennett JL, Thomas S, Olson JL, Mandava N. Treatment of nonarteritic anterior ischemic optic neuropathy with intravitreal bevacizumab. J Neuroophthalmol. 2007;27:238–40.PubMedCrossRef
10.
Kaderli B, Avci R, Yucel A, Guler K, Gellisken O. Intravitreal triamcinolone improves recovery of visual acuity in nonarteritic ischemic optic neuropathy. J Neuroophthalmol. 2007;27:164–8.PubMedCrossRef
11.
Sergott RC, Cohen MS, Bosley TM, Savino PJ. Optic nerve decompression may improve the progressive form of nonarteritic ischemic optic neuropathy. Arch Ophthalmol. 1989;177:1743–54.CrossRef
12.
Kelman SE. Intravitreal triamcinolone or bevacizumab for nonarteritic anterior ischemic optic neuropathy: do they merit further study? J Neuroophthalmol. 2007;3:161–3.CrossRef
13.
Bernstein SL, Johnson MA, Miller NR. Nonarteritic anterior ischemic optic neuropathy (NAION) and its experimental models. Prog Retin Eye Res. 2011;30:167–87.PubMedCrossRef
14.
Chuman H, Maekubo T, Oosako T, Kodama Y, Ishiai M, Nao-I N. Rodent model of nonarteritic ischemic optic neuropathy and its electrophysiological evaluation. Jpn J Ophthalmol. 2012;56:518–27.PubMedCrossRef
15.
Maekubo T, Chuman H, Kodama Y, Nao-I N. Evaluation of the retinal nerve fiber thickness around the optic disc using optical coherence tomography of rodent model of nonarteritic ischemic optic neuropathy. Jpn J Ophthalmol. 2013;57:327–32.
16.
Nakai T, Hishikawa K, Suzuki H, Saruta T, Kato R. l-Arginine-induced hypotension. Lancet. 1990;336:696.CrossRef
17.
18.
Chiou GYC, Liu SXL, Li BHP, Chiang CH, Varma RS. Ocular hypotensive effect of l-arginine and its derivatives and their actions on ocular blood flow. J Ocul Pharmacol Ther. 1995;11:1–10.PubMedCrossRef
19.
Urabe K, Matsumura Y, Nonaka H, Nishiura M, Maeda K, Morimoto S. Role of endogenous angiotensin II in renal hemodynamic and excretory responses to l-arginine infusion. Biol Pharm Bull. 1996;19:1149–53.PubMedCrossRef
20.
Tsao PS, Teilmeier G, Singer AH, Leung LL, Cooke JP. l-Arginine attenuates platelet reactivity in hypercholesterolemic rabbits. Arterioscler Thromb. 1994;14:1529–33.PubMedCrossRef
21.
Marietta M, Facchinetti F, Neri I, Volpe A, Torelli G. l-Arginine infusion decreases platelet aggregation through an intraplatelet nitric oxide release. Thromb Res. 1997;88:229–35.PubMedCrossRef
22.
Cooke JP, Dzau VJ. Derangements of the nitric oxide synthase pathway, l-arginine, and cardiovascular diseases. Circulation. 1997;96:379–82.PubMed
23.
Harston GWJ, Sutherland BA, Kennedy J, Buchan AM. The contribution of l-arginine to the neurotoxicity of recombinant tissue plasminogen activator following cerebral ischemia: a review of rtPA neurotoxicity. J Cereb Blood Flow Metab. 2010;30:1804–16.PubMedCrossRef
24.
Koga Y, Ishibashi M, Ueki I, Yatsuga S, Fukiyama R, Akita Y, et al. Effects of l-arginine on acute phase of strokes in three patients with MELAS. Neurology. 2002;58:827–8.PubMedCrossRef
25.
Koga Y, Akita Y, Nishioka J, Yatsuga S, Povalko N, Tanabe Y, et al. l-Arginine improves the symptoms of stroke-like episodes in MELAS. Neurology. 2005;64:710–2.PubMedCrossRef
26.
Bernstein SL, Guo Y, Kelman SE, Flower RW, Johnson MA. Functional and cellular responses in a novel rodent model of anterior ischemic optic neuropathy. Invest Ophthalmol Vis Sci. 2003;44:4153–62.PubMedCrossRef
27.
Campbell MC, Hughes A. An analytic, gradient index schematic lens and eye for the rat which predicts aberrations for finite pupils. Vis Res. 1981;21:1129–48.PubMedCrossRef
28.
Guo L, Normando M, Nizari S, Lara D, Cordeiro M. Tracking longitudinal retinal changes in experimental ocular hypertension using the cSLO and Spectral domain OCT. Invest Ophthalmol Vis Sci. 2010;51:6503–12.
29.
McLeod D, Marshall J, Kohner EM. Role of axoplasmic transport in the pathophysiology of ischaemic disc swelling. Br J Ophthalmol. 1980;64:247–61.PubMedCrossRef
30.
Grieshaber P, Lageze WA, Noack C, Boehringer D, Biermann J. Staining of fluorogold-prelabeled retinal ganglion cells with calcein-AM: a new method for assessing cell vitality. J Neurosci Methods. 2010;192:233–9.PubMedCrossRef
31.
Tagami Y, Kurimoto T, Miyoshi T, Morimoto T, Sawai H, Mimura O. Axonal regeneration induced by repetitive electrical stimulation of crushed optic nerve in adult rats. Jpn J Ophthalmol. 2009;53:257–66.PubMedCrossRef
32.
Jehle T, Wingert K, Dimitriu C, Meschede W, Lasseck J, Bach M, et al. Quantification of ischemic damage in the rat retina: a comparative study using evoked potentials, electroretinography, and histology. Invest Ophthalmol Vis Sci. 2008;49:1056–64.PubMedCrossRef
33.
Hayreh SS. Optic disc edema in raised intracranial pressure V. Pathogenesis. Arch Ophthalmol. 1977;95:1553–65.PubMedCrossRef
34.
Hayreh SS, Massanari RM, Yamada T, Hayreh SM. Experimental allergic encephalomyelitis I. Optic nerve and central nervous system manifestations. Invest Ophthalmol Vis Sci. 1981;21:256–69.PubMed
35.
36.
Böger RH, Bode-Böger SM. The clinical pharmacology of l-arginine. Annu Rev Pharmacol Toxicol. 2001;41:79–99.PubMedCrossRef
37.
Drexler H, Zeiher AM, Meinzer K, Just H. Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by l-arginine. Lancet. 1991;338:1546–50.PubMedCrossRef
38.
Bednarz B, Jaxa-Chamiec T, Maciejewski P, Szpajer M, Janik K, Gniot J, et al. Efficacy and safety of oral l-arginine in acute myocardial infarction. Results of the multicenter, randomized, double-blind, placebo-controlled ARAMI pilot trial. Kardiol Pol. 2005;62:421–7.PubMed
39.
Schulman SP, Becker LC, Kass DA, Champion SC, Terrin ML, Forman S, et al. l-Arginine therapy in acute myocardial infarction: the Vascular Interaction With Age in Myocardial Infarction (VINTAGE MI) randomized clinical trial. JAMA. 2006;295:58–64.PubMedCrossRef
40.
Koga Y, Akita Y, Junko N, Yatsuga S, Povalko N, Fukiyama R, et al. Endothelial dysfunction in MELAS improved by l-arginine supplementation. Neurology. 2006;66:1766–9.PubMedCrossRef
Metadata
Title
Effects of l-arginine on anatomical and electrophysiological deterioration of the eye in a rodent model of nonarteritic ischemic optic neuropathy
Authors
Hideki Chuman
Tomoyuki Maekubo
Takako Osako
Michitaka Ishiai
Naoko Kawano
Nobuhisa Nao-i
Publication date
01-07-2013
Publisher
Springer Japan
Published in
Japanese Journal of Ophthalmology / Issue 4/2013
Print ISSN: 0021-5155
Electronic ISSN: 1613-2246
DOI
https://doi.org/10.1007/s10384-013-0250-z

Other articles of this Issue 4/2013

Japanese Journal of Ophthalmology 4/2013 Go to the issue

Clinical Investigation

Tenon advancement and duplication technique to prevent postoperative Ahmed valve tube exposure in patients with refractory glaucoma

Clinical Investigation

Cost-utility analysis of cataract surgery in Japan: a probabilistic Markov modeling study

Clinical Investigation

Influence of decorative lenses on higher-order wavefront aberrations

Clinical Investigation

Clinical features of human T lymphotropic virus type 1-associated uveitis in Hokkaido, Japan

Clinical Investigation

Comparison of two different spectral domain optical coherence tomography devices in the detection of localized retinal nerve fiber layer defects

Laboratory Investigation

Effects of steroid administration and transcorneal electrical stimulation on the anatomic and electrophysiologic deterioration of nonarteritic ischemic optic neuropathy in a rodent model